Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 101
interventional 55
Observational 41
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 15
Drug|placebo 11
Other 9
Diagnostic Test 4
Drug|Procedure 3
Biological|Drug|Radiation 2
Behavioral|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other 1
Biological|Procedure 1
Device 1
Device|Other|Procedure 1
Drug|Other 1
Drug|Radiation 1
Other|Procedure 1
placebo|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 19
Brazil 3
Canada 3
Italy 3
China 2
Denmark 2
Spain 2
United Kingdom 2
United States|Canada|Switzerland 2
Austria 1
Egypt 1
France 1
Germany 1
Greece 1
Hong Kong 1
Japan 1
Korea, Republic of 1
Lithuania 1
NA 1
Netherlands 1
Switzerland 1
Tanzania 1
Turkey 1
United States|Australia|Canada 1
United States|Australia|Canada|Netherlands|Puerto Rico|Switzerland 1
United States|Puerto Rico|Saudi Arabia 1

Sites per Study

Site_count Study_Count
1 36
2 8
4 2
10 1
14 1
19 1
39 1
61 1
63 1
148 1
174 1
559 1

Phase

Phase Study_Count
N/A 23
Phase 3 13
Phase 2 9
Phase 1 4
Phase 4 3
Early Phase 1 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 10
2 31
3 6
4 3
8 1
NA 4

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 20 5.0000 3.0 70 34.0000 144 13.0000 90
1st Qu. 20 59.0000 12.0 70 94.0000 144 200.0000 102
Median 20 128.0000 31.5 70 122.0000 144 253.0000 114
Mean 20 154.2609 44.0 70 190.2222 144 311.7692 118
3rd Qu. 20 195.0000 63.5 70 300.0000 144 398.0000 132
Max. 20 597.0000 110.0 70 468.0000 144 817.0000 150

Trial Group Type

group_type Group_Count
Experimental 57
Active Comparator 20
Placebo Comparator 12
No Intervention 11
Other 10
NA 4

Intervention Model

intervention_model Study_Count
Parallel Assignment 35
Single Group Assignment 19
Crossover Assignment 1

Primary Purpose

primary_purpose Study_Count
Prevention 21
Treatment 16
Supportive Care 7
Diagnostic 5
Screening 3
Basic Science 2
Other 1

Observational Studies

Studies by Country

Country Study_Count
United States 16
France 5
Canada 2
Italy 2
Korea, Republic of 2
Netherlands 2
United States|Canada 2
Australia 1
China 1
Denmark 1
Denmark|Finland|Iceland|Ireland|Netherlands|Norway|Sweden 1
Egypt 1
Germany 1
Ireland 1
Poland 1
Russian Federation 1
Slovenia 1

Sites per Study

Site_count Study_Count
1 27
2 5
3 2
4 1
6 1
13 1
14 1
15 1
20 1
105 1

Enrollment Metrics

Measure Observational
Min 12.0000
1st Qu 45.0000
Median 128.0000
Mean 920.7317
3rd Qu 220.0000
Max 20000.0000

Observation Model

observational_model Study_Count
Cohort 26
Case-Only 8
Case-Control 4
Case-Crossover 1
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 35
Retrospective 4
Cross-Sectional 1
NA 1

Registries

Studies by Country

Country Study_Count
United States 2
China 1
Israel 1
Spain 1

Sites per Study

Site_count Study_Count
1 4
2 1

Enrollment Metrics

Measure Registries
Min 55
1st Qu 65
Median 110
Mean 272
3rd Qu 130
Max 1000

Registry Model

observational_model Study_Count
Cohort 4
Other 1

Time Perspective

time_perspective Study_Count
Prospective 5

Follow-up

target_duration Study_Count
1 Year 2
2 Years 1
5 Years 1
6 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03862131 PROactive Evaluation of Function to Avoid CardioToxicity https://ClinicalTrials.gov/show/NCT03862131 Recruiting Washington University School of Medicine 2022-12-31
NCT04092309 Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT04092309 Recruiting University of Athens 2020-09-01
NCT03418961 S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer https://ClinicalTrials.gov/show/NCT03418961 Recruiting Southwest Oncology Group 2023-02-01
NCT03186404 Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study https://ClinicalTrials.gov/show/NCT03186404 Recruiting University Health Network, Toronto 2020-12-31
NCT03166813 Remote Ischaemic Preconditioning in Childhood Cancer https://ClinicalTrials.gov/show/NCT03166813 Recruiting The University of Hong Kong 2020-09-30
NCT02943590 STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines) https://ClinicalTrials.gov/show/NCT02943590 Recruiting Massachusetts General Hospital 2021-06-30
NCT02942615 The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy. https://ClinicalTrials.gov/show/NCT02942615 Recruiting Ruijin Hospital 2019-12-31
NCT02909712 Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania https://ClinicalTrials.gov/show/NCT02909712 Active, not recruiting London School of Hygiene and Tropical Medicine 2020-01-31
NCT02796365 Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy https://ClinicalTrials.gov/show/NCT02796365 Completed Henry Ford Health System 2018-12-31
NCT02666378 Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer https://ClinicalTrials.gov/show/NCT02666378 Recruiting Dana-Farber Cancer Institute 2020-12-31
NCT02652975 Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium https://ClinicalTrials.gov/show/NCT02652975 Completed University of Aarhus 2018-06-30
NCT02605512 BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study https://ClinicalTrials.gov/show/NCT02605512 Recruiting Institut de Radioprotection et de Surete Nucleaire 2019-09-30
NCT03389724 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03389724 Recruiting Children’s Cancer Hospital Egypt 57357 2020-11-14
NCT02471885 Effect of Remote Ischaemic Conditioning in Oncology Patients https://ClinicalTrials.gov/show/NCT02471885 Recruiting University College, London 2020-12-31
NCT02471053 Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study https://ClinicalTrials.gov/show/NCT02471053 Completed Nova Scotia Health Authority 2017-09-30
NCT02236806 Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab https://ClinicalTrials.gov/show/NCT02236806 Recruiting Azienda Ospedaliero-Universitaria Careggi 2021-07-31
NCT02177175 Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification https://ClinicalTrials.gov/show/NCT02177175 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-06-30
NCT02096588 Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin https://ClinicalTrials.gov/show/NCT02096588 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2017-04-25
NCT02053974 Spironolactone Against Anthracycline-induced Cardiomyopathy https://ClinicalTrials.gov/show/NCT02053974 Completed TC Erciyes University 2012-10-31
NCT01968200 Prevention of Anthracycline-induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT01968200 Active, not recruiting European Institute of Oncology 2019-12-31
NCT01724450 Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT01724450 Completed University of Sao Paulo 2017-06-30
NCT04429633 Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer https://ClinicalTrials.gov/show/NCT04429633 Recruiting Samsung Medical Center 2022-07-18
NCT04105634 Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT https://ClinicalTrials.gov/show/NCT04105634 Active, not recruiting University of Pennsylvania 2021-10-01
NCT04047901 Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment https://ClinicalTrials.gov/show/NCT04047901 Recruiting University of Sao Paulo General Hospital 2021-02-28
NCT04044872 Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT04044872 Recruiting University of Texas Southwestern Medical Center 2021-10-31
NCT04030546 Ivabradine to Prevent Anthracycline-induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT04030546 Recruiting Vilnius University 2020-06-01
NCT04023110 Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab https://ClinicalTrials.gov/show/NCT04023110 Recruiting Abramson Cancer Center of the University of Pennsylvania 2022-02-28
NCT03964142 Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT03964142 Recruiting Hospital Clinico Universitario de Santiago 2020-08-01
NCT03940625 Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping https://ClinicalTrials.gov/show/NCT03940625 Recruiting Heinrich-Heine University, Duesseldorf 2022-12-31
NCT03934905 Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction https://ClinicalTrials.gov/show/NCT03934905 Recruiting Texas Tech University Health Sciences Center 2021-06-01
NCT03850171 Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study https://ClinicalTrials.gov/show/NCT03850171 Recruiting University Hospital Inselspital, Berne 2021-03-31
NCT03711110 Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) https://ClinicalTrials.gov/show/NCT03711110 Recruiting Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León 2024-08-02
NCT03645317 Avoiding Cardiac Toxicity in Lung Cancer Patients Treated With Curative-intent Radiotherapy https://ClinicalTrials.gov/show/NCT03645317 Recruiting The Christie NHS Foundation Trust 2020-04-01
NCT03553654 Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT03553654 Recruiting University of California, San Diego 2021-01-09
NCT03486340 Prevention of Chest Pain in Chemo-treated Cancer Patients https://ClinicalTrials.gov/show/NCT03486340 Recruiting Vejle Hospital 2021-12-31
NCT01230983 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01230983 Completed Children’s Oncology Group 2001-09-30
NCT01032278 Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT) https://ClinicalTrials.gov/show/NCT01032278 Active, not recruiting M.D. Anderson Cancer Center 2020-01-31
NCT01009918 Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab https://ClinicalTrials.gov/show/NCT01009918 Completed University of South Florida 2017-08-31
NCT00854568 Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL https://ClinicalTrials.gov/show/NCT00854568 Completed Fudan University 2012-12-31
NCT01719562 MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum https://ClinicalTrials.gov/show/NCT01719562 Recruiting Wake Forest University Health Sciences 2021-05-31
NCT03650205 Ivabradine to Prevent Anthracycline-induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT03650205 Recruiting University of Sao Paulo 2021-10-01
NCT00577798 Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin https://ClinicalTrials.gov/show/NCT00577798 Completed University of Nebraska 2012-12-31
NCT00575406 Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00575406 Completed Arbeitsgemeinschaft medikamentoese Tumortherapie 2012-01-31
NCT00543062 Staccato Prochlorperazine Thorough QT/QTc https://ClinicalTrials.gov/show/NCT00543062 Completed Alexza Pharmaceuticals, Inc. 2007-12-31
NCT00530101 The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity https://ClinicalTrials.gov/show/NCT00530101 Completed University of Miami 2008-03-31
NCT00459771 Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity https://ClinicalTrials.gov/show/NCT00459771 Completed The Netherlands Cancer Institute 2013-12-31
NCT00436566 Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery https://ClinicalTrials.gov/show/NCT00436566 Completed Mayo Clinic 2009-04-30
NCT00292526 Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients https://ClinicalTrials.gov/show/NCT00292526 Completed European Institute of Oncology 2011-11-30
NCT00247975 Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy https://ClinicalTrials.gov/show/NCT00247975 Completed Ottawa Heart Institute Research Corporation 2010-10-31
NCT00162955 Prevention of CHOP-induced Chronic Cardiotoxicity https://ClinicalTrials.gov/show/NCT00162955 Completed Osaka City University 2010-09-30
NCT00005578 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00005578 Completed Children’s Oncology Group 2004-10-31
NCT00002827 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00002827 Completed Children’s Oncology Group 2004-10-31
NCT00003070 Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer https://ClinicalTrials.gov/show/NCT00003070 Completed Children’s Oncology Group 2003-07-31
NCT00039481 Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00039481 Completed National Cancer Institute (NCI) 2005-10-31
NCT00003937 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma https://ClinicalTrials.gov/show/NCT00003937 Completed Children’s Oncology Group 2004-03-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02615054 Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors https://ClinicalTrials.gov/show/NCT02615054 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-11-30
NCT03301389 Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest) https://ClinicalTrials.gov/show/NCT03301389 Recruiting Yonsei University 2025-01-31
NCT03259711 Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase https://ClinicalTrials.gov/show/NCT03259711 Completed Groupe Hospitalier Pitie-Salpetriere 2017-08-14
NCT03243604 cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study https://ClinicalTrials.gov/show/NCT03243604 Completed Groupe Hospitalier Pitie-Salpetriere 2017-07-13
NCT03235427 The CAROLE (CArdiac Related Oncologic Late Effects) Study https://ClinicalTrials.gov/show/NCT03235427 Completed Northwell Health 2018-06-26
NCT03193138 CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS) https://ClinicalTrials.gov/show/NCT03193138 Completed Groupe Hospitalier Pitie-Salpetriere 2017-06-21
NCT03155802 Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines https://ClinicalTrials.gov/show/NCT03155802 Recruiting Stony Brook University 2020-12-31
NCT02916316 Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell https://ClinicalTrials.gov/show/NCT02916316 Recruiting Fondazione Italiana Linfomi ONLUS 2020-12-31
NCT02875171 Assessment of Global Longitudinal Strain for the Prediction of Anthracycline Induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT02875171 Completed Versailles Hospital 2015-05-31
NCT02798679 Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity https://ClinicalTrials.gov/show/NCT02798679 Recruiting University of Minnesota 2020-12-31
NCT02769299 Cardiotoxicity of Radiation Therapy (CTRT) https://ClinicalTrials.gov/show/NCT02769299 Completed Abramson Cancer Center of the University of Pennsylvania 2018-11-26
NCT02440620 Cardiac Toxicity in Medical Treatment of Breast Cancer https://ClinicalTrials.gov/show/NCT02440620 Completed Odense University Hospital 2018-08-31
NCT02423356 Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin https://ClinicalTrials.gov/show/NCT02423356 Completed Indiana University 2018-02-01
NCT02306538 Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI https://ClinicalTrials.gov/show/NCT02306538 Recruiting University Health Network, Toronto 2020-10-31
NCT02274480 Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT02274480 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-10-31
NCT02086695 Early Detection of Broken Hearts in Cancer Patients https://ClinicalTrials.gov/show/NCT02086695 Completed Mayo Clinic 2015-09-30
NCT02065908 Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer https://ClinicalTrials.gov/show/NCT02065908 Completed West Pomeranian Cancer Center 2016-06-30
NCT01805778 Preventing Cardiac Sequelae in Pediatric Cancer Survivors https://ClinicalTrials.gov/show/NCT01805778 Completed The Hospital for Sick Children 2018-09-30
NCT01671696 Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy https://ClinicalTrials.gov/show/NCT01671696 Recruiting Connecticut Children’s Medical Center 2020-05-31
NCT01665300 Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT01665300 Completed Seoul National University Hospital 2013-12-31
NCT01572883 Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer https://ClinicalTrials.gov/show/NCT01572883 Completed Institute of Oncology Ljubljana 2012-07-31
NCT04409379 Association Between Telomere Length and Cardiac Dysfunction https://ClinicalTrials.gov/show/NCT04409379 Completed Fourth Military Medical University 2020-05-01
NCT04262830 Cancer Therapy Effects on the Heart https://ClinicalTrials.gov/show/NCT04262830 Recruiting University of California, San Diego 2021-09-30
NCT04191265 Cardiotoxicity of Aluminum Phosphide Poisoning; Tropinin and CKmb as Early Biomarkers https://ClinicalTrials.gov/show/NCT04191265 Active, not recruiting Assiut University 2020-06-05
NCT04055636 Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. https://ClinicalTrials.gov/show/NCT04055636 Recruiting Moscow State University of Medicine and Dentistry 2021-06-30
NCT04046315 Early Detection of Cardiac Damage With CMR in Women With Breast Cancer https://ClinicalTrials.gov/show/NCT04046315 Recruiting Radboud University 2021-03-31
NCT04036032 Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy https://ClinicalTrials.gov/show/NCT04036032 Recruiting Connecticut Children’s Medical Center 2021-06-30
NCT03930394 Vascular Cardiotoxicity of Ponatinib https://ClinicalTrials.gov/show/NCT03930394 Recruiting Oregon Health and Science University 2021-05-01
NCT03882580 Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care https://ClinicalTrials.gov/show/NCT03882580 Recruiting Groupe Hospitalier Pitie-Salpetriere 2025-03-01
NCT03543228 MyoStrain CMR for the Detection of Cardiotoxicity https://ClinicalTrials.gov/show/NCT03543228 Active, not recruiting Myocardial Solutions 2018-12-31
NCT03480087 Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma https://ClinicalTrials.gov/show/NCT03480087 Recruiting Azienda Ospedaliera Città della Salute e della Scienza di Torino 2020-07-31
NCT01246778 Sunitinib and Atrial Trabeculae Contractility https://ClinicalTrials.gov/show/NCT01246778 Completed Radboud University 2014-04-30
NCT01173341 Cardiotoxicity of Cancer Therapy (CCT) https://ClinicalTrials.gov/show/NCT01173341 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2029-04-30
NCT01014065 A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) https://ClinicalTrials.gov/show/NCT01014065 Completed AHS Cancer Control Alberta 2012-11-30
NCT00968682 CADY Study ICORG 08-01 https://ClinicalTrials.gov/show/NCT00968682 Completed Cancer Trials Ireland 2014-04-30
NCT00875238 Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab https://ClinicalTrials.gov/show/NCT00875238 Completed Vanderbilt University Medical Center 2015-03-31
NCT00858039 Cardiotoxicity of Adjuvant Trastuzumab https://ClinicalTrials.gov/show/NCT00858039 Completed Royal Prince Alfred Hospital, Sydney, Australia 2013-07-31
NCT04260269 Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study https://ClinicalTrials.gov/show/NCT04260269 Enrolling by invitation Helsinki University Central Hospital 2020-12-31
NCT00806507 Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients https://ClinicalTrials.gov/show/NCT00806507 Completed M.D. Anderson Cancer Center 2011-08-31
NCT00636844 Detection of Chemotherapy Induced Cardiotoxicity https://ClinicalTrials.gov/show/NCT00636844 Completed George Washington University 2011-12-31
NCT00002900 SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial https://ClinicalTrials.gov/show/NCT00002900 Completed Southwest Oncology Group 2008-03-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04461223 Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR https://ClinicalTrials.gov/show/NCT04461223 Recruiting Second Affiliated Hospital, School of Medicine, Zhejiang University 2021-12-01
NCT02818517 Evaluation and Management of Cardio Toxicity in Oncologic Patients https://ClinicalTrials.gov/show/NCT02818517 Recruiting Tel-Aviv Sourasky Medical Center 2030-11-30
NCT04026737 Cardiovascular Effects of CART Cell Therapy https://ClinicalTrials.gov/show/NCT04026737 Recruiting Abramson Cancer Center of the University of Pennsylvania 2021-07-31
NCT03981588 Cardiotoxicity in the Elderly https://ClinicalTrials.gov/show/NCT03981588 Active, not recruiting AORTICA Group 2016-12-31
NCT03760237 Cardiovascular Function in Acute Leukemia https://ClinicalTrials.gov/show/NCT03760237 Enrolling by invitation Abramson Cancer Center of the University of Pennsylvania 2021-12-31